• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核局灶黏着激酶诱导 APC/C 激活蛋白 CDH1 介导的细胞周期蛋白依赖性激酶 4/6 降解,从而抑制黑色素瘤增殖。

Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.

机构信息

Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, Alabama, USA.

出版信息

J Biol Chem. 2022 Jun;298(6):102013. doi: 10.1016/j.jbc.2022.102013. Epub 2022 May 5.

DOI:10.1016/j.jbc.2022.102013
PMID:35525274
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9163754/
Abstract

Dysregulation of cyclin-dependent kinases (CDKs) can promote unchecked cell proliferation and cancer progression. Although focal adhesion kinase (FAK) contributes to regulating cell cycle progression, the exact molecular mechanism remains unclear. Here, we found that FAK plays a key role in cell cycle progression potentially through regulation of CDK4/6 protein expression. We show that FAK inhibition increased its nuclear localization and induced G1 arrest in B16F10 melanoma cells. Mechanistically, we demonstrate nuclear FAK associated with CDK4/6 and promoted their ubiquitination and proteasomal degradation through recruitment of CDC homolog 1 (CDH1), an activator and substrate recognition subunit of the anaphase-promoting complex/cyclosome E3 ligase complex. We found the FAK N-terminal FERM domain acts as a scaffold to bring CDK4/6 and CDH1 within close proximity. However, overexpression of nonnuclear-localizing mutant FAK FERM failed to function as a scaffold for CDK4/6 and CDH1. Furthermore, shRNA knockdown of CDH1 increased CDK4/6 protein expression and blocked FAK inhibitor-induced reduction of CDK4/6 in B16F10 cells. In vivo, we show that pharmacological FAK inhibition reduced B16F10 tumor size, correlating with increased FAK nuclear localization and decreased CDK4/6 expression compared with vehicle controls. In patient-matched healthy skin and melanoma biopsies, we found FAK was mostly inactive and nuclear localized in healthy skin, whereas melanoma lesions showed increased active cytoplasmic FAK and elevated CDK4 expression. Taken together, our data demonstrate that FAK inhibition blocks tumor proliferation by inducing G1 arrest, in part through decreased CDK4/6 protein stability by nuclear FAK.

摘要

细胞周期蛋白依赖性激酶(CDKs)的失调可促进不受控制的细胞增殖和癌症进展。尽管粘着斑激酶(FAK)有助于调节细胞周期进程,但确切的分子机制尚不清楚。在这里,我们发现 FAK 通过调节 CDK4/6 蛋白表达在细胞周期进程中发挥关键作用。我们表明,FAK 抑制增加了其核定位并诱导 B16F10 黑色素瘤细胞中的 G1 期阻滞。在机制上,我们证明核 FAK 与 CDK4/6 相关,并通过募集细胞分裂周期蛋白 1(CDH1)促进它们的泛素化和蛋白酶体降解,CDH1 是后期促进复合物/细胞周期蛋白 E3 连接酶复合物的激活剂和底物识别亚基。我们发现 FAK N 端 FERM 结构域充当支架,使 CDK4/6 和 CDH1 紧密接近。然而,过表达非核定位的突变体 FAK FERM 不能作为 CDK4/6 和 CDH1 的支架发挥作用。此外,CDH1 的 shRNA 敲低增加了 CDK4/6 蛋白表达,并阻止了 FAK 抑制剂诱导的 B16F10 细胞中 CDK4/6 的减少。在体内,我们表明,与载体对照相比,药理 FAK 抑制可降低 B16F10 肿瘤大小,这与 FAK 的核定位增加和 CDK4/6 表达降低相关。在患者匹配的健康皮肤和黑色素瘤活检中,我们发现 FAK 在健康皮肤中主要是无活性和核定位的,而黑色素瘤病变显示出增加的活性细胞质 FAK 和 CDK4 表达升高。总之,我们的数据表明,FAK 抑制通过诱导 G1 期阻滞来阻止肿瘤增殖,部分原因是核 FAK 降低 CDK4/6 蛋白稳定性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702c/9163754/e519e9ed614d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702c/9163754/e519e9ed614d/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702c/9163754/e519e9ed614d/gr1.jpg

相似文献

1
Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.核局灶黏着激酶诱导 APC/C 激活蛋白 CDH1 介导的细胞周期蛋白依赖性激酶 4/6 降解,从而抑制黑色素瘤增殖。
J Biol Chem. 2022 Jun;298(6):102013. doi: 10.1016/j.jbc.2022.102013. Epub 2022 May 5.
2
APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor-induced arrest.后期促进复合物/细胞周期体(APC/C)可防止细胞周期蛋白/细胞周期蛋白依赖性激酶(cyclin/CDK)活性出现非经典顺序,以维持CDK4/6抑制剂诱导的细胞停滞。
Proc Natl Acad Sci U S A. 2024 Jul 23;121(30):e2319574121. doi: 10.1073/pnas.2319574121. Epub 2024 Jul 18.
3
Combined Inactivation of Pocket Proteins and APC/C by Cdk4/6 Controls Recovery from DNA Damage in G1 Phase.Cdk4/6 通过同时抑制口袋蛋白和 APC/C 来控制 G1 期 DNA 损伤后的细胞周期恢复。
Cells. 2021 Mar 4;10(3):550. doi: 10.3390/cells10030550.
4
CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G phase to initiate a new cell cycle in HeLa cells.在有丝分裂过程中,CDK4蛋白通过后期促进复合物/细胞周期体降解,并在G1期早期重新积累,从而在HeLa细胞中启动新的细胞周期。
J Biol Chem. 2017 Jun 16;292(24):10131-10141. doi: 10.1074/jbc.M116.773226. Epub 2017 Apr 26.
5
FAK in the nucleus prevents VSMC proliferation by promoting p27 and p21 expression via Skp2 degradation.FAK 在核内通过促进 Skp2 降解来增加 p27 和 p21 的表达,从而阻止 VSMC 增殖。
Cardiovasc Res. 2022 Mar 16;118(4):1150-1163. doi: 10.1093/cvr/cvab132.
6
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.涉及 MET 和 FAK 的信号转导支持细胞分裂,而不依赖于细胞周期调节 CDK4/6 激酶的活性。
Oncogene. 2019 Jul;38(30):5905-5920. doi: 10.1038/s41388-019-0850-2. Epub 2019 Jul 12.
7
Hippo signaling is intrinsically regulated during cell cycle progression by APC/C.Hippo 信号通路在细胞周期进程中通过 APC/C 进行内在调节。
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9423-9432. doi: 10.1073/pnas.1821370116. Epub 2019 Apr 18.
8
Cdk5-mediated inhibition of APC/C-Cdh1 switches on the cyclin D1-Cdk4-pRb pathway causing aberrant S-phase entry of postmitotic neurons.细胞周期蛋白依赖性激酶5(Cdk5)介导的后期促进复合物/细胞分裂周期蛋白1(APC/C-Cdh1)抑制作用开启了细胞周期蛋白D1-细胞周期蛋白依赖性激酶4-视网膜母细胞瘤蛋白(cyclin D1-Cdk4-pRb)信号通路,导致有丝分裂后神经元异常进入S期。
Sci Rep. 2015 Dec 10;5:18180. doi: 10.1038/srep18180.
9
The HECT type ubiquitin ligase NEDL2 is degraded by anaphase-promoting complex/cyclosome (APC/C)-Cdh1, and its tight regulation maintains the metaphase to anaphase transition.HECT 型泛素连接酶 NEDL2 被后期促进复合物/周期蛋白(APC/C)-Cdh1 降解,其严格的调控维持着有丝分裂向后期的转变。
J Biol Chem. 2013 Dec 13;288(50):35637-50. doi: 10.1074/jbc.M113.472076. Epub 2013 Oct 25.
10
KEN-box-dependent degradation of the Bub1 spindle checkpoint kinase by the anaphase-promoting complex/cyclosome.后期促进复合物/细胞周期体对Bub1纺锤体检查点激酶的KEN框依赖性降解
J Biol Chem. 2007 Feb 9;282(6):3672-9. doi: 10.1074/jbc.M609376200. Epub 2006 Dec 11.

引用本文的文献

1
Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma.核黏着斑激酶对卵巢癌顺铂应激具有保护作用。
Cancer Res Commun. 2024 Dec 1;4(12):3165-3179. doi: 10.1158/2767-9764.CRC-24-0382.
2
Activation of the Anaphase Promoting Complex Restores Impaired Mitotic Progression and Chemosensitivity in Multiple Drug-Resistant Human Breast Cancer.后期促进复合体的激活可恢复多药耐药性人类乳腺癌中受损的有丝分裂进程和化学敏感性。
Cancers (Basel). 2024 Apr 30;16(9):1755. doi: 10.3390/cancers16091755.
3
CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.

本文引用的文献

1
FAK in the nucleus prevents VSMC proliferation by promoting p27 and p21 expression via Skp2 degradation.FAK 在核内通过促进 Skp2 降解来增加 p27 和 p21 的表达,从而阻止 VSMC 增殖。
Cardiovasc Res. 2022 Mar 16;118(4):1150-1163. doi: 10.1093/cvr/cvab132.
2
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma.细胞周期蛋白依赖性激酶抑制剂在黑色素瘤治疗中的研究进展。
CDKN2A/B纯合缺失使异柠檬酸脱氢酶(IDH)突变型胶质瘤对细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制敏感。
Clin Cancer Res. 2024 Jul 15;30(14):2996-3005. doi: 10.1158/1078-0432.CCR-24-0562.
4
Roles and inhibitors of FAK in cancer: current advances and future directions.黏着斑激酶在癌症中的作用及抑制剂:当前进展与未来方向
Front Pharmacol. 2024 Feb 12;15:1274209. doi: 10.3389/fphar.2024.1274209. eCollection 2024.
5
Ubiquitin-proteasome system as a target for anticancer treatment-an update.泛素-蛋白酶体系统作为抗癌治疗的靶点——更新。
Arch Pharm Res. 2023 Jul;46(7):573-597. doi: 10.1007/s12272-023-01455-0. Epub 2023 Aug 5.
Expert Opin Pharmacother. 2021 Feb;22(3):351-361. doi: 10.1080/14656566.2020.1828348. Epub 2020 Oct 8.
4
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.黑色素瘤中获得性BRAF抑制剂耐药机制:一项系统综述
Cancers (Basel). 2020 Sep 29;12(10):2801. doi: 10.3390/cancers12102801.
5
Targeting focal adhesion kinase in cancer cells and the tumor microenvironment.靶向肿瘤细胞和肿瘤微环境中的黏着斑激酶。
Exp Mol Med. 2020 Jun;52(6):877-886. doi: 10.1038/s12276-020-0447-4. Epub 2020 Jun 9.
6
Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update.抗程序性死亡蛋白1(Anti-PD-1)及其新型联合疗法治疗黑色素瘤的最新进展
J Clin Med. 2020 Jan 14;9(1):223. doi: 10.3390/jcm9010223.
7
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
8
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤(KEYNOTE-006):一项开放标签、多中心、随机、对照、III 期研究的 5 年随访后结果。
Lancet Oncol. 2019 Sep;20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2. Epub 2019 Jul 22.
9
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases.涉及 MET 和 FAK 的信号转导支持细胞分裂,而不依赖于细胞周期调节 CDK4/6 激酶的活性。
Oncogene. 2019 Jul;38(30):5905-5920. doi: 10.1038/s41388-019-0850-2. Epub 2019 Jul 12.
10
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.CTLA-4 和 PD-1 抑制剂联合治疗癌症。
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255. doi: 10.1186/s13046-019-1259-z.